32 completed, 17 recruiting, 16 terminated, 11 active not recruiting. 87 Phase 1, 31 Phase 2.
Follow Myelofibrosis: new trials by email Literature Review of Myelofibrosis trials Research Report on Myelofibrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Revumenib in Patients With Myelofibrosis Revumenib, Ruxolitinib, FEDRATINIB - Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 1 / Phase 2 | Not yet recruiting | John Mascarenhas | 32 | 2026-12-01 | 2026-07-29 |
| A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant Biospecimen Collection, Electronic Health Record Review, Haploidentical Hematopoietic Cell Transplantation - Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | City of Hope Medical Center | 46 | 2026-09-09 | 2026-10-23 |
| Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis ropeginterferon alfa- 2b, Ruxolitinib - Myelofibrosis | Phase 1 | Recruiting | University of Utah | 15 | 2026-08-21 | 2026-10-19 |
| QT Interval/Corrected QT Interval (QT/QTc) Clinical Study to Evaluate the Cardiac Safety of TQ05105 Tablets in Healthy Participants TQ05105 tablets, Placebo tablets, Moxifloxacin Hydrochloride Tablets - Myelofibrosis | Phase 1 | Active not recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 60 | 2026-07-30 | 2026-08-07 |
| Study to Evaluate the Effect of Rabeprazole Sodium Enteric-coated Tablets on the Pharmacokinetics of TQ05105 Tablets TQ05105 tablets, Rabeprazole sodium enteric-coated tablets - Myelofibrosis | Phase 1 | Active not recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 17 | 2026-07-20 | 2026-07-27 |
| A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis rebecsinib - Secondary AML, Myelofibrosis | Phase 1 | Recruiting | Aspera Biomedicines, Inc. | 28 | 2026-05-21 | 2026-07-20 |
| To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Hepatic Impairment Subjects TQ05105 - Myelofibrosis | Phase 1 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 24 | 2026-04-01 | 2026-04-06 |
| Momelotinib During and After HCT in Myelofibrosis Momelotinib - Myelofibrosis, Hematopoietic Cell Transplantation (HCT) | Phase 1 | Recruiting | Massachusetts General Hospital | 28 | 2026-02-23 | 2026-03-31 |
| Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow Nelfinavir - Myelofibrosis, Myelofibrosis; Anemia | Phase 1 / Phase 2 | Recruiting | University of California, Irvine | 10 | 2025-09-16 | 2026-10-26 |
| Tasquinimod in Patients with Myelofibrosis Refractory to or Intolerant for JAK2 Inhibition Tasquinimod - Myelofibrosis | Phase 1 / Phase 2 | Recruiting | Stichting Hemato-Oncologie voor Volwassenen Nederland | 20 | 2025-02-20 | 2025-03-07 |
| A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis Ulixertinib, Ruxolitinib - Myelofibrosis | Phase 1 / Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 37 | 2025-01-07 | 2026-07-28 |
| To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Renal Impairment Subjects TQ05105 - Myelofibrosis | Phase 1 | Completed | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 32 | 2024-10-12 | 2025-08-24 |
| A Safety and Tolerability Study of Jaktinib Jaktinib Hydrochloride Tablet - Myelofibrosis | Phase 1 | Unknown | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 26 | 2024-07-01 | 2024-03-21 |
| A Study of GLB-001 in Patients With Myeloid Malignancies GLB-001 - Polycythemia Vera, Essential Thrombocythemia | Phase 1 | Recruiting | Hangzhou GluBio Pharmaceutical Co., Ltd. | 108 | 2024-05-24 | 2025-08-19 |
| A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF) TQ05105 tablets, TQB3909 tablets - Myelofibrosis | Phase 1 / Phase 2 | Terminated | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 21 | 2024-05-13 | 2026-01-05 |
| A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF) TQ05105 Tablets, TQB3617 Capsules - Myelofibrosis | Phase 1 / Phase 2 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 92 | 2023-12-12 | 2025-12-08 |
| Comparative Study on Pharmacokinetics of Two Formulations of Jaktinib in Healthy Adults Under Fasting Conditions Jaktinib Hydrochloride Tablets - Myelofibrosis | Phase 1 | Completed | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 52 | 2023-11-29 | 2024-01-11 |
| A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets TQ05105 tablets, Itraconazole capsule, Rifampicin Capsule - Myelofibrosis | Phase 1 | Completed | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 40 | 2023-09-21 | 2025-12-12 |
| AlloHCT With PegINFa for Myelofibrosis Pegylated interferon alpha2a - Myelofibrosis | Phase 1 | Recruiting | University of Utah | 18 | 2023-08-02 | 2026-10-27 |
| Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm Peptide-based vaccine, Poly ICLC - Myelofibrosis, Essential Thrombocythemia | Phase 1 | Active not recruiting | Marina Kremyanskaya | 7 | 2023-04-04 | 2026-09-28 |
Showing 20 of 87. Sign in to see all of them.
Primary Myelofibrosis (87) · Myelodysplastic Syndromes (20) · Leukemia, Myeloid, Acute (19) · Myeloproliferative Disorders (18) · Polycythemia Vera (12) · Thrombocythemia, Essential (12) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (10) · Leukemia, Lymphocytic, Chronic, B-Cell (9) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (9) · Leukemia, Myelomonocytic, Chronic (9) · Lymphoma, Non-Hodgkin (9) · Hodgkin Disease (6) · Lymphoma (6) · Multiple Myeloma (6) · Hematologic Neoplasms (5)
Hemic and Lymphatic Diseases (87) · Bone Marrow Diseases (85) · Hematologic Diseases (84) · Myeloproliferative Disorders (69) · Neoplasms (40) · Neoplasms by Histologic Type (29) · Leukemia, Myeloid (24) · Leukemia (23) · Disease Attributes (22) · Pathologic Processes (22) · Pathological Conditions, Signs and Symptoms (22) · Chronic Disease (21) · Neoplasms by Site (20) · Hemorrhagic Disorders (18) · Immune System Diseases (18)
ruxolitinib (24) · 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (5) · fedratinib (4) · fludarabine (4) · Busulfan (3) · Decitabine (3) · N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide (3) · Stem Cell Transplantation (3) · Azacitidine (2) · Cyclophosphamide (2) · Injections (2) · Methotrexate (2) · Mycophenolic Acid (2) · NIS-793 (2) · Tacrolimus (2)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (9) · Novartis Pharmaceuticals (4) · Incyte Corporation (3) · John Mascarenhas (3) · Suzhou Zelgen Biopharmaceuticals Co.,Ltd (3) · Bristol-Myers Squibb (2) · CTI BioPharma (2) · City of Hope Medical Center (2) · Kartos Therapeutics, Inc. (2) · M.D. Anderson Cancer Center (2) · S*BIO (2) · University of California, Irvine (2) · University of Utah (2) · American Regent, Inc. (1) · Asana BioSciences (1)
United States (62) · Germany (15) · Italy (15) · China (14) · Australia (10) · France (10) · United Kingdom (9) · Canada (8) · Spain (8) · Netherlands (6) · Poland (5) · Austria (3) · Israel (3) · South Korea (3) · Belgium (2)
Ayalew Tefferi, MD (3) · John Mascarenhas, MD (3) · Ronald Hoffman, MD (2) · Andrea Bacigalupo, MD (1) · Andrew Roberts, M.D. (1) · Angela Fleischman, MD, PhD (1) · Angela Flesichman, MD, PhD (1) · Anthony M Hunter, MD (1) · Bik To, MD (1) · Camelia Iancu-Rubin, PhD (1) · Camille Abboud, M.D. (1)
PMID 20843246, PMID 22718840, PMID 23682558, PMID 24355079, PMID 25563429, PMID 25762180, PMID 27931243, PMID 29544547, PMID 30249277, PMID 31778911, PMID 32396615, PMID 33718228, PMID 36105914, PMID 36125208, PMID 36594185, PMID 36881782, PMID 37530627, PMID 38259250, PMID 39924599, PMID 40241543, PMID 40334082, PMID 40752760, PMID 40919483, PMID 41146971, PMID 41758981, PMID 42054549, PMID 42855460
2018 (3), 2019 (3), 2023 (2), P01CA108671 (2), 2014 (1), 2015 (1), P01CA229092 (1), P30CA033572 (1), P50CA100632 (1)